Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
10 pending office actions • 3 art units • 8 examiners • 0 of 10 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Spinalcyte LLC holds a company patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently has 10 pending office actions. These actions are distributed among 8 distinct examiners, indicating a broad range of simultaneous reviews across the patent office. This high volume of pending actions requires a robust management strategy to handle the various deadlines and examiner requirements. The diversity of examiners suggests that the company is engaging with a wide cross-section of the USPTO's expertise in biotechnology.
The workload is situated within 3 distinct art units, which suggests some technical concentration despite the high number of examiners involved. MIANO, JOSEPH PAUL is the busiest examiner, currently overseeing 2 pending office actions. This distribution shows that while most examiners handle a single matter, MIANO, JOSEPH PAUL manages a larger share of the 10 pending actions compared to the other distinct examiners in the portfolio. For the company, this means that while the technical scope is limited to 3 art units, the prosecution experience will vary significantly across the 8 distinct examiners. Practitioners must account for the different styles and rejection patterns of these multiple examiners while maintaining consistency across the 3 art units.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (20%) |
| §112 only | 1 (10%) |
| Double-patenting + other | 1 (10%) |
| Multi-statute (no §101) | 6 (60%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MIANO, JOSEPH PAUL | 2 | 36.0% | +63.3% |
| PYLA, EVELYN Y | 2 | 55.7% | +47.1% |
| JOHNSON, KARA D | 1 | 69.5% | +24.6% |
| ALDARONDO, DASIA ALI | 1 | 0.0% | +0.0% |
| SCHUBERG, LAURA J | 1 | 23.6% | +37.0% |
| FOX, ALLISON M | 1 | 71.2% | +35.7% |
| SINGH, ANOOP KUMAR | 1 | 43.0% | +67.6% |
| CORDAS, EMILY ANN | 1 | 50.8% | +57.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17453143 | FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE | PYLA, EVELYN Y | 52d overdue |
| 17755837 | FIBROBLAST-BASED THERAPY FOR TREATMENT AND PREVENTION OF STROKE | FOX, ALLISON M | 20d |
| 18905224 | TREATMENT OF OPIOID ADDICTION USING FIBROBLASTS AND PRODUCTS THEREOF | JOHNSON, KARA D | — |
| 18570530 | FIBROBLAST BASED THERAPEUTICS OF AMYOTROPHIC LATERAL SCLEROSIS | ALDARONDO, DASIA ALI | — |
| 17996392 | TREATMENT OF FRONTOTEMPORAL DEMENTIA USING FIBROBLASTS AND PRODUCTS THEREOF | SCHUBERG, LAURA J | — |
| 17052845 | INTRADISCAL T-REGULATORY CELL ADMINISTRATION FOR TREATMENT OF DISC DEGENERATIVE DISEASE | SINGH, ANOOP KUMAR | — |
| 16068096 | CELLULAR BLEND FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS | CORDAS, EMILY ANN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17453143 | FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE | PYLA, EVELYN Y | 52d overdue |
| 17052841 | DE-DIFFERENTIATED FIBROBLAST-CONDITIONED MEDIA FOR STIMULATION OF DISC REGENERATION | MIANO, JOSEPH PAUL | 36d overdue |
| 17755837 | FIBROBLAST-BASED THERAPY FOR TREATMENT AND PREVENTION OF STROKE | FOX, ALLISON M | 20d |
| 18905224 | TREATMENT OF OPIOID ADDICTION USING FIBROBLASTS AND PRODUCTS THEREOF | JOHNSON, KARA D | — |
| 18345022 | DE-DIFFERENTIATED FIBROBLAST-CONDITIONED MEDIA FOR STIMULATION OF DISC REGENERATION | MIANO, JOSEPH PAUL | — |
| 17996392 | TREATMENT OF FRONTOTEMPORAL DEMENTIA USING FIBROBLASTS AND PRODUCTS THEREOF | SCHUBERG, LAURA J | — |
| 17052845 | INTRADISCAL T-REGULATORY CELL ADMINISTRATION FOR TREATMENT OF DISC DEGENERATIVE DISEASE | SINGH, ANOOP KUMAR | — |
| 16068096 | CELLULAR BLEND FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS | CORDAS, EMILY ANN | — |
| Art Unit | Apps |
|---|---|
| 1631 | 3 |
| 1633 | 3 |
| 1632 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18905224 | TREATMENT OF OPIOID ADDICTION USING FIBROBLASTS AND PRODUCTS THEREOF | JOHNSON, KARA D | — | §103§112 | Non-Final OA | — | Pending | Oct 03, 2024 |
| 18570530 | FIBROBLAST BASED THERAPEUTICS OF AMYOTROPHIC LATERAL SCLEROSIS | ALDARONDO, DASIA ALI | — | §103§112DP | Non-Final OA | — | Pending | Dec 14, 2023 |
| 18345022 | DE-DIFFERENTIATED FIBROBLAST-CONDITIONED MEDIA FOR STIMULATION OF DISC REGENERATION | MIANO, JOSEPH PAUL | 1631 | §103Other | Non-Final OA | — | Pending | Jun 30, 2023 |
| 17996392 | TREATMENT OF FRONTOTEMPORAL DEMENTIA USING FIBROBLASTS AND PRODUCTS THEREOF | SCHUBERG, LAURA J | 1631 | §102§103 | Final Rejection | — | Pending | Oct 17, 2022 |
| 17755837 | FIBROBLAST-BASED THERAPY FOR TREATMENT AND PREVENTION OF STROKE | FOX, ALLISON M | 1633 | §103§112Other | Non-Final OA | 20d | Pending | May 10, 2022 |
| 17453143 | FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE | PYLA, EVELYN Y | 1633 | §103§112 | Non-Final OA | 52d overdue | Pending | Nov 01, 2021 |
| 17052841 | DE-DIFFERENTIATED FIBROBLAST-CONDITIONED MEDIA FOR STIMULATION OF DISC REGENERATION | MIANO, JOSEPH PAUL | 1631 | §103Other | Final Rejection | 36d overdue | Pending | Nov 04, 2020 |
| 17052845 | INTRADISCAL T-REGULATORY CELL ADMINISTRATION FOR TREATMENT OF DISC DEGENERATIVE DISEASE | SINGH, ANOOP KUMAR | 1632 | §103§112 | Non-Final OA | — | Pending | Nov 04, 2020 |
| 16068096 | CELLULAR BLEND FOR THE REGENERATION OF CHONDROCYTES OR CARTILAGE TYPE CELLS | CORDAS, EMILY ANN | 1632 | §103§112 | Final Rejection | — | Pending | Dec 17, 2018 |
| 14357558 | FIBROBLASTS FOR TREATMENT OF DEGENERATIVE DISC DISEASE | PYLA, EVELYN Y | 1633 | §112 | Final Rejection | — | Pending | May 09, 2014 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial